<DOC>
	<DOCNO>NCT02609022</DOCNO>
	<brief_summary>Study CV-0002 first clinical trial administer CV-MG01 human . This clinical trial safety proof-of-concept study ( proof mechanism action ) intend assess safety , tolerability immunogenic response follow 3 subcutaneous injection CV-MG01 potential therapeutic vaccine / active immunotherapy myasthenia gravis ( MG ) patient .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenic Response CV-MG01 Patients With Myasthenia Gravis</brief_title>
	<detailed_description>Part A trial design human safety pharmacology therapeutic exploratory , parallel group , randomise , placebo-controlled , single centre , Investigator subject-blind study use adaptive dose sample size approach . At end part A present study , patient , include receive placebo , monitor open label , long-term safety follow-up part B study ass treatment effect time .</detailed_description>
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Acetylcholine</mesh_term>
	<criteria>Male female subject , ocular generalise myasthenia gravis ( grade 123 ) . Between age 18 64 year , inclusive , time first injection . A Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive . Patient positive antibody AChR base radioimmunoassay ( RIA ) ( AChRAb â‰¥ 1 nmol/l ) ; available , historical data AChR Ab level last 2 year collect study record . Patient may use corticosteroid treatment , equivalent daily dose 30 mg prednisone lower stable ( dose +/ 5 mg ) 3 month participation . Patient may use one immunosuppressive drug without concomitant use corticosteroid , provide dosage stable/unchanged 3 month participation . Blood pressure heart rate ( supine &amp; standing ) within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator . Venous access sufficient allow blood sample per protocol . Are reliable willing make available duration study willing follow study procedure . Have give write informed consent approve relevant Ethics Committee ( EC ) govern site . MG patient Grade 4 5 base myasthenia gravis foundation America ( MGFA ) classification . Patients history presence primary recurrent malignant disease include presence history thymoma . Thymectomy plan part A study period perform within 1 year prior first dose study vaccine . Any confirm suspected immunosuppressive immunodeficient condition relate treatment MG , include human immunodeficiency virus ( HIV ) infection , family history congenital hereditary immunodeficiency . History evidence administration immunoglobulins and/or blood product within 3 month prior first dose study vaccine plan administration immunoglobulin first 3 month trial . History evidence rituximab treatment within 6 month prior first dose study vaccine . History evidence plasmapheresis within 3 month prior first dose study vaccine plan plasmapheresis first 3 month trial . At high risk aspiration . Pulmonary : force vital capacity reduce less 70 % predict capacity . History severe allergic disease reaction likely exacerbate component vaccine . History evidence LambertEaton myasthenic syndrome , druginduced myasthenia gravis , hereditary form myasthenic syndrome . History relevant chronic degenerative , psychiatric , neurological disorder MG . Severe hepatic , renal cardiac insufficiency . Major congenital defect serious chronic illness MG . Positive pregnancy test desire become pregnant study . Female patient childbearing potential use reliable highly effective method contraception least one month first injection , study 3 month last injection . Any significant outofrange Clinical Laboratory result consider clinically significant accord Investigator 's judgment . Previous completion withdrawal study . Sponsor employee investigator site personnel directly affiliate study , immediate family . Immediate family define spouse , parent , child sibling , whether biological legally adopt . Any medical condition , opinion Investigator , might interfere subject 's participation study , pose add risk subject , confound assessment subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myasthenia Gravis</keyword>
	<keyword>CV-MG01 therapeutic vaccine</keyword>
	<keyword>Acetylcholine receptor mimetic peptide</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenic response</keyword>
	<keyword>First-in-Human</keyword>
	<keyword>Proof-of-Concept</keyword>
	<keyword>Myasterix</keyword>
</DOC>